The eliquis market in the United States is expected to reach a projected revenue of US$ 5,443.8 million by 2033. A compound annual growth rate of -1.9% is expected of the United States eliquis market from 2025 to 2033.
In terms of revenue, U.S. accounted for 28.2% of the global eliquis market in 2024.
Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
In North America, U.S. eliquis market is projected to lead the regional market in terms of revenue in 2033.
Mexico is the fastest growing regional market in North America and is projected to reach USD 264.8 million by 2033.
The U.S. holds the largest share in the North America Eliquis (apixaban) market owing to strong physician preference for DOACs in stroke prevention and VTE treatment. The country has a large base of patients requiring long-term anticoagulation due to high rates of cardiovascular disease.
Insurance coverage and formulary inclusion have facilitated consistent access to the drug. Real-world data and comparative studies have positioned Eliquis favorably against other anticoagulants. Marketing and educational initiatives by Bristol Myers Squibb and Pfizer sustain brand visibility. The growing elderly population and sedentary lifestyles continue to expand the market scope.
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Eliquis Market Outlook will help companies and investors design strategic landscapes.
Atrial Fibrillation (Af) was the largest segment with a revenue share of 68.16% in 2024.
Horizon Databook has segmented the U.S. eliquis market based on atrial fibrillation (af), deep vein thrombosis (dvt), pulmonary embolism (pe), post-operative vte prophylaxis (at-risk cases) covering the revenue growth of each sub-segment from 2021 to 2033.
The U.S. holds the largest share in the North America Eliquis (apixaban) market owing to strong physician preference for DOACs in stroke prevention and VTE treatment. The country has a large base of patients requiring long-term anticoagulation due to high rates of cardiovascular disease.
Insurance coverage and formulary inclusion have facilitated consistent access to the drug. Real-world data and comparative studies have positioned Eliquis favorably against other anticoagulants. Marketing and educational initiatives by Bristol Myers Squibb and Pfizer sustain brand visibility. The growing elderly population and sedentary lifestyles continue to expand the market scope.
U.S. Eliquis Market Indication Outlook (Revenue, USD Million , 2021-2033)
Atrial Fibrillation (AF)
Deep Vein Thrombosis (DVT)
Pulmonary Embolism (PE)
Post-Operative VTE Prophylaxis (at-risk cases)
Others
U.S. Eliquis Market Distribution Channel Outlook (Revenue, USD Million , 2021-2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Reasons to subscribe to Eliquis Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Eliquis Market Outlook databook
Our clientele includes a mix of Eliquis Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. Eliquis Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into U.S. Eliquis Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.